Group One Trading’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.2M | Buy |
2,246,900
+913,300
| +68% | +$6.25M | 0.03% | 559 |
|
|
2025
Q4 | $2.64M | Sell |
1,333,600
-90,800
| -6% | -$206K | ﹤0.01% | 2031 |
|
|
2025
Q3 | $3.5M | Buy |
1,424,400
+584,600
| +70% | +$1.51M | 0.01% | 1805 |
|
|
2025
Q2 | $2.22M | Buy |
839,800
+24,200
| +3% | +$65.1K | ﹤0.01% | 2037 |
|
|
2025
Q1 | $2.45M | Buy |
815,600
+272,000
| +50% | +$824K | 0.01% | 1647 |
|
|
2024
Q4 | $1.39M | Buy |
543,600
+197,900
| +57% | +$824K | ﹤0.01% | 2243 |
|
|
2024
Q3 | $1.29M | Sell |
345,700
-241,700
| -41% | -$1.12M | ﹤0.01% | 2097 |
|
|
2024
Q2 | $3.71M | Buy |
587,400
+246,300
| +72% | +$1.62M | 0.01% | 993 |
|
|
2024
Q1 | $1.83M | Buy |
341,100
+216,900
| +175% | +$982K | 0.01% | 1552 |
|
|
2023
Q4 | $623K | Sell |
124,200
-496,600
| -80% | -$1.56M | ﹤0.01% | 2881 |
|
|
2023
Q3 | $1.05M | Sell |
620,800
-34,600
| -5% | -$69.5K | ﹤0.01% | 2220 |
|
|
2023
Q2 | $1.82M | Buy |
655,400
+642,200
| +4,865% | +$1.82M | 0.01% | 1791 |
|
|
2023
Q1 | $24K | Sell |
13,200
-60,600
| -82% | -$188K | ﹤0.01% | 5385 |
|
|
2022
Q4 | $374K | Sell |
73,800
-4,000
| -5% | -$22K | ﹤0.01% | 3309 |
|
|
2022
Q3 | $387K | Buy |
77,800
+32,100
| +70% | +$146K | ﹤0.01% | 3488 |
|
|
2022
Q2 | $170K | Sell |
45,700
-22,200
| -33% | -$89.2K | ﹤0.01% | 4455 |
|
|
2022
Q1 | $381K | Buy |
67,900
+39,900
| +143% | +$245K | ﹤0.01% | 4113 |
|
|
2021
Q4 | $170K | Buy |
28,000
+4,100
| +17% | +$30.8K | ﹤0.01% | 5241 |
|
|
2021
Q3 | $233K | Sell |
23,900
-17,400
| -42% | -$191K | ﹤0.01% | 5010 |
|
|
2021
Q2 | $590K | Sell |
41,300
-335,100
| -89% | -$5.54M | ﹤0.01% | 4036 |
|
|
2021
Q1 | $8.94M | Sell |
376,400
-6,400
| -2% | -$166K | 0.01% | 1022 |
|
|
2020
Q4 | $5.1M | Buy |
382,800
+307,200
| +406% | +$2.96M | 0.01% | 1263 |
|
|
2020
Q3 | $524K | Sell |
75,600
-10,500
| -12% | -$105K | ﹤0.01% | 2800 |
|
|
2020
Q2 | $1.06M | Buy |
86,100
+61,100
| +244% | +$345K | ﹤0.01% | 1969 |
|
|
2020
Q1 | $72K | Buy |
25,000
+1,300
| +5% | +$6.51K | ﹤0.01% | 3513 |
|
|
2019
Q4 | $90K | Buy |
23,700
+10,800
| +84% | +$18.4K | ﹤0.01% | 3704 |
|
|
2019
Q3 | $16K | Hold |
12,900
| – | – | ﹤0.01% | 4433 |
|
|
2019
Q2 | $13K | Sell |
12,900
-17,100
| -57% | -$19.7K | ﹤0.01% | 4336 |
|
|
2019
Q1 | $47K | Buy |
30,000
+12,200
| +69% | +$15.3K | ﹤0.01% | 3598 |
|
|
2018
Q4 | $21K | Buy |
+17,800
| New | +$40.7K | ﹤0.01% | 4003 |
|
|
2018
Q1 | – | Sell |
-1,000
| Closed | -$4K | – | 5041 |
|
|
2017
Q4 | $4K | Sell |
1,000
-3,800
| -79% | -$18K | ﹤0.01% | 4608 |
|
|
2017
Q3 | $26K | Buy |
4,800
+300
| +7% | +$1.85K | ﹤0.01% | 3941 |
|
|
2017
Q2 | $34K | Buy |
+4,500
| New | +$19.4K | ﹤0.01% | 3703 |
|
|
2016
Q3 | – | Sell |
-1,500
| Closed | -$9K | – | 4695 |
|
|
2016
Q2 | $9K | Sell |
1,500
-1,000
| -40% | -$7.76K | ﹤0.01% | 4108 |
|
|
2016
Q1 | $21K | Buy |
2,500
+500
| +25% | +$4.71K | ﹤0.01% | 3716 |
|
|
2015
Q4 | $35K | Buy |
+2,000
| New | +$29.7K | ﹤0.01% | 3619 |
|
Other funds holding IBRX
VPM
VCM
HF
WP
Group One Trading's IBRX Position: Q1 2026 in Review
Group One Trading sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 766,908 shares — an estimated $5.25M sold.
Group One Trading first reported a position in IBRX in Q4 2015 and held it in 25 quarters. The position peaked at $4.05M in Q1 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.
- Group One Trading reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
- Group One Trading sold 766,908 ImmunityBio shares in Q1 2026, an estimated $5.25M.
- Group One Trading first reported a position in ImmunityBio in Q4 2015 and held it in 25 quarters.
- Group One Trading's ImmunityBio position peaked at $4.05M in Q1 2025.
- 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.